Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
| Autor: | Jason J. Luke, Christopher C. Frohne, Ernesto M. Llano, Ashley Perkovic, Russell D. Cohen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Male Crohn’s disease Cancer Research medicine.medical_specialty Integrins medicine.medical_treatment Immunology Population Programmed Cell Death 1 Receptor Case Report Pembrolizumab Metastatic melanoma Antibodies Monoclonal Humanized lcsh:RC254-282 Vedolizumab Immune system Crohn Disease Internal medicine Antineoplastic Combined Chemotherapy Protocols Autoimmune disease medicine Immunology and Allergy Humans Immune checkpoint inhibitor therapy education Melanoma Pharmacology Immunosuppression Therapy Crohn's disease education.field_of_study business.industry Immunotherapy Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immune checkpoint Treatment Outcome Immune related adverse event Molecular Medicine business medicine.drug |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019) Journal for Immunotherapy of Cancer |
| ISSN: | 2051-1426 |
| Popis: | Background Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being treated for autoimmune conditions, and there is only limited evidence that these treatments are safe and effective in this population of patients. Case presentation We present a case of a man with Crohn’s disease actively requiring immunosuppressive therapy who subsequently received pembrolizumab for metastatic melanoma. He had no further progression of metastatic disease and had resolution of his pulmonary nodule while he experienced no Crohn’s disease flares or immune related adverse events. We surveyed the existing literature for studies examining the use of ICPIs in patients with autoimmune disorders and reviewed the unique mechanism of action of the α4β7 inhibitor, vedolizumab. Conclusion Patients with autoimmune conditions should be considered candidates for immune checkpoint inhibition even in the setting of active immunosuppressive therapy. The mechanism of action of immunosuppressive therapy should be considered with the most targeted form of treatment being used when possible. Further prospective studies investigating immunotherapy in patients with autoimmune conditions are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink